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METHODS
Endovascular stent-graft device. The Talent device
is a self-expanding, modular stent-graft system composed
of serpentine-shaped nitinol stents inlaid in woven poly-
ester fabric (Fig 1). The stents are spaced along a full-
length nitinol spine. The latter provides longitudinal
(column) strength to a graft that is otherwise flexible to
accommodate aorto-iliac angulations. The delivery system
is composed of a coaxial sheath with an internal pusher
rod and a compliant polyurethane balloon that is sequen-
tially inflated to maximize apposition of the graft to the
vessel wall target zones and to ensure full expansion of the
device along its length. The basic components of the
Talent AAA system are a bifurcated main section and a
contralateral iliac limb. Available configurations include
the Free-Flo graft with a 15-mm long uncovered stent at
the proximal end to allow transrenal or suprarenal fixa-
tion. Additional modular components include aortic cuffs
and iliac extensions. The manufacturer offers customiza-
tion in a variety of configurations and sizes (length and
diameters).2 Diameter ranges are 16 to 36 mm for the
aortic section and 8 to 22 mm for the iliac limbs.
Clinical studies. Several studies have assessed the
safety and efficacy of the Talent stent-graft in the treat-
ment of AAA. The clinical evaluation study designs
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Purpose: Phase I and phase II trials were conducted to determine the safety and efficacy of the Talent aortic stent-graft
(Medtronic World Medical, Sunrise, Fla) in the treatment of infrarenal abdominal aortic aneurysms (AAA). This is a pre-
liminary report of the technical results and 30-day clinical outcome of these trials.
Methods: Multicenter prospective trials were conducted to test the Talent stent-graft in high-risk and low-risk patient pop-
ulations with AAA, including phase I feasibility and phase II clinical trials. The low-risk study included concurrent sur-
gical controls.
Results: In the phase I trial, deployment success was achieved in 92% (23/25 patients), and initial technical success was
78% (18/23 implants without endoleak). The 30-day technical success rate was 96%, with six endoleaks that resolved
spontaneously (without need for further intervention); and the 30-day mortality rate was 12% (3/25 patients). The
phase II high-risk trial demonstrated a deployment success of 94% (119/127 patients) and an initial technical success of
86% (102/119 implants). The 30-day technical success rate was 96%, and the 30-day mortality rate was 1.5% (2/127
patients). The phase II low-risk trial included a first-generation and a second-generation Talent stent-graft. Deployment
success rates were 97% and 99%, respectively, and technical success rates at 30 days were 97% and 96%, respectively. The
30-day mortality rate was 2% in the phase II low-risk first-generation device trial, and the adverse-event rate was 20%.
Corresponding figures for the second-generation device were 0% and 1.8%, respectively.
Conclusion: The Talent stent-graft can be deployed successfully and achieves endovascular exclusion in a large proportion
of patients with AAA. Morbidity and mortality rates are acceptable. One-year clinical results and the comparison with
concurrent surgical control subjects remain to be evaluated. (J Vasc Surg 2001;33:S146-9.)
The Talent stent-graft (Medtronic World Medical,
Sunrise, Fla) is an endovascular device that is undergoing
clinical investigation to test its efficacy in the treatment of
thoracic and abdominal aortic aneurysms (AAAs).
Approximately 10,000 Talent stent-graft implantations
have been performed worldwide since December 1995.
Several studies have been conducted after US Food
and Drug Administration approval of the investigational
device exemption in April 1997.1 In this preliminary
report, we present the technical and 30-day results
obtained in the US phase I and phase II AAA trials. One-
year clinical results and comparison with concurrent surgi-
cal controls from Phase II will be the subject of a
subsequent report.
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included a phase I feasibility study involving six investiga-
tional sites to demonstrate device and procedure safety
before the expansion to multiple phase II controlled studies
(in adherence to the US Food and Drug Administration
guidelines) that involve several designs. The phase II stud-
ies were conducted at 17 investigational sites. In one arm
(low-risk trial), endovascular repair was compared with stan-
dard operation as performed concurrently on surgical con-
trol patients who were selected on the basis of unsuitable
anatomy for endovascular repair or a refusal to undergo the
stent-graft procedure. (The control data will appear in a
subsequent report.)
Endovascular stent-graft procedure. The Talent
stent-graft AAA procedure was performed with general,
epidural/spinal, or local anesthesia and involved bilateral
groin incisions for exposure of the common femoral arter-
ies. The use of adjunctive brachial artery catheterization
was according to individual discretion. Imaging from a
fixed or mobile fluoroscopy system and power-injector
angiography were used to guide the placement of the
stent-graft. Aorto-uniiliac implantations required con-
tralateral iliac artery exclusion by surgical ligation, coil
embolization (or a combination of the two), and crossover
femorofemoral bypass grafting.
Definitions and criteria. Risk factor stratification
adhered to The Society for Vascular Surgery/International
Society for Cardiovascular Surgery guidelines,3,4 with risk-
level scores of 0, 1, or 2 being deemed as “low risk” and 3
as “high risk.” Deployment success was defined as the ability
to deliver the stent-graft device into position as intended.
Technical success was defined as successful deployment with-
out endoleak. Adverse events were defined as any compli-
cation that required additional procedures and/or
prolonged hospitalization (ie, arterial rupture or dissec-
tion, renal dysfunction, lower extremity ischemia, signifi-
cant cardiac or respiratory complications, and conversion
to surgery).
Follow-up evaluation. Patients underwent abdomi-
nal radiography and contrast/noncontrast spiral com-
puted tomography scans before discharge to evaluate
device placement, patency of the graft, aneurysm size,
renal artery patency, and presence or absence of endoleak.
These studies were reviewed locally at each site and at an
independent core laboratory facility. After discharge, the
patients were evaluated at 1 month, 6 months, 1 year, and
yearly thereafter.
RESULTS
Phase I high-risk. In the phase I feasibility trial, 25
patients with infrarenal AAA were enrolled at six centers.
The average aneurysm size was 61 ± 15 mm, with 24 male
and one female patients. Nearly one half of the patients (12
patients) had severe coronary artery disease; five patients had
a ventricular ejection fraction of less than 30%. Deployment
success was achieved in 23 of 25 patients (92%). In two
patients, deployment failed because of delivery/access diffi-
culties. These two cases were immediately converted to open
aneurysm repair; one of the patients died in the postopera-
tive period. The overall 30-day mortality rate was 12% (3/25
patients). The technical success rate at initial deployment was
78%, with seven of 23 implanted showing evidence of an
endoleak at the completion of the stent-graft procedure.
Some of these endoleaks were retrospectively attributed to
“contrast blush” through the graft. At 30 days, only one
patient had a persistent endoleak on computed tomography
scan, for a 96% 30-day technical success rate. The other
endoleaks closed spontaneously. Adverse events were identi-
fied in 10 patients (40%) and included limb ischemia,
myocardial infarction, congestive heart failure, renal failure,
and groin wound infections (Table I).
Phase II high-risk. One hundred twenty-seven
patients at 17 centers qualified for the phase II high-risk
trial that used either the bifurcated Talent stent-graft
design or the aorto-uniiliac configuration with a femoro-
femoral bypass. The mean aneurysm diameter was 57 ± 10
mm. All patients were found to be high risk, with 15% of
the patients having an ejection fraction of less than 20, and
10% of the patients being over the age of 90 years. Ninety-
nine patients received the bifurcated device; 28 patients
received an aorto-uniiliac stent-graft. Deployment success
was achieved in 94% of the patients (119/127 patients),
with deployment failure in eight patients. Initial technical
success (absence of endoleak) was documented in 102
patients (86%). Success at 30 days was found to be 96%
(114/119 patients). The adverse-event rate was 14.9%
(19/127 patients), the most common complications
Table I. Summary of deployment, technical success, clinically adverse events, and mortality rates associated with the
four arms of the Talent stent-graft trials for the treatment of AAA
30-Day (%)
Clinical Deployment success Technical success Technical success Adverse event Mortality
trial rate (%) rate (%) rate rate rate
Phase I high-risk feasibility 92 (23/25) 78 (18/23) 96 (22/23) 40 (10/25) 12 (3/25)
Phase II high-risk 94 (119/127) 86 (102/119) 96 (114/119) 14.9 (19/127) 1.5 (2/127)
Phase II low-risk (first-generation) 97 (147/151) 88 (130/147) 97 (138/142) 20 (29/142) 2 (3/142)
Phase II low-risk (second-generation) 99 (167/168) 80 (133/167) 96 (68/71) 4 (3/71) 0
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being renal failure, congestive heart failure, and graft limb
thrombosis. Two of the 127 patients (1.5%) died; one
patient had overwhelming disseminated intravascular
coagulopathy, and the other patient experienced a fatal
myocardial infarction on day 30 (Table I).
Phase II low-risk (first-generation device). This
phase II trial used the first generation Talent stent-graft
and delivery system, both of which were later modified
and resubmitted under an additional investigational device
exemption. One hundred fifty-one patients were selected
under the low-risk inclusion criteria. Successful deploy-
ment was realized in 147 patients (97%), with initial tech-
nical success in 130 patients (88%). Ninety-seven percent
of patients (138/142 evaluated) were free of endoleaks at
30 days. Adverse events were seen in 29 of 142 patients
(20%) and included arterial dissection or rupture in seven
patients, renal failure in six patients, ischemia of the lower
extremities in two patients, myocardial infarction in five
patients, respiratory complications in three patients,
arrhythmias in three patients, and conversion to open
surgery in four patients. The 30-day mortality rate was 2%
(three patients). Causes of death included respiratory fail-
ure in two patients and myocardial infarction in one
patient (Table I).
Phase II low-risk (second-generation device). The
original Talent stent-graft and delivery system evolved into
the low-profile system and was evaluated in a separate clin-
ical study. Low-risk criteria were observed in 168 patients
who were enrolled in this arm of the trial. A concurrent
surgical control population was also evaluated, the results
of which will be reported subsequently with the 1-year
data. Deployment was successful in 99% of the patients
(167/168 patients), and initial technical success was
achieved in 80% of the patients (133 patients). Thirty-day
success (no endoleak) was seen in 68 of 71 patients (96%)
who were available for evaluation. Procedure-related com-
plications included one patient with a thrombosed stent-
graft limb, another patient with respiratory failure, and an
additional patient with postoperative paraplegia from
spinal cord ischemia. No patients died during the proce-
dure or the initial 30-day follow-up (zero mortality rate;
Table I).
DISCUSSION
Despite ongoing doubt5 and recent concerns sur-
rounding clinical efficacy and durability,6 stent-graft repair
of AAA is by far the most exciting development in vascu-
lar surgery in many years. All clinical investigators recog-
nize the somewhat “unfinished” nature of endoluminal
graft technology that, by all accounts, is still in its
“infancy.” Future developments will likely address the
major unresolved issues, mainly deliverability to the aortic
lumen, reliable fixation in challenging proximal necks and,
foremost, the ability to adjust to evolving morphologic
changes (as the excluded aneurysm shrinks) without dis-
connections, dislocations, or migration. The occurrence of
endoleaks and the potential for late aneurysm rupture
after stent-graft repair continue to be causes for concern.
The Talent stent-graft has proved versatile in the treat-
ment of a wide range of aortic aneurysms of various mor-
phologic conditions. It is the only currently available
commercially produced device that is capable of addressing
AAA necks larger than 28 mm in diameter.7 Customization
Fig 1. The modular bifurcated Talent aortic stent-graft. Note the
“bare spring” proximal nitinol stent configuration for trans- and
suprarenal fixation.
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capabilities (as offered by the manufacturer) have provided
a niche for the Talent technology and made it distinct in
the stent-graft field. Interestingly, such characteristics (and
the fact that initial investigational device exemption
approval in the United States was for high-risk patients
only) have resulted in the application of the Talent device
in a disproportionately large percentage of surgically unfit
patients. Morbidity and mortality rates in some of the stud-
ies clearly reflect its use in such anatomically and medically
disadvantaged patient population. It would be fair to state
that the Talent stent-graft is the one device that many, if
not most, investigators around the world resort to for large
aortic necks and “difficult AAA anatomy.”
The data reflect the technical performance of the
device and 30-day clinical outcome obtained at 17 investi-
gational centers in the United States. The Talent aortic
stent-graft appears to be an effective device for the
endovascular exclusion of AAA. The thinner-graft low-pro-
file system (Talent low profile system) has been a particu-
larly welcome evolution, which has resulted in a decrease of
procedure-related adverse events from 20% to just under
5%. The 1-year clinical results (currently undergoing audit-
ing and tabulation) and a comparison with concurrent sur-
gical controls will be published at a later time.
The principal investigators at the 17 investigational
sites for the US Talent AAA trials: Frank J. Criado, MD;
Gary Becker, MD; Barry T. Katzen, MD; Frank J. Veith,
MD; Renan Uflacker, MD; Edward B. Diethrich, MD;
Michael Belkin, MD; Michael Hallisey, MD; Michael
Khoury, MD; Paul Bove, MD; Alexander Balko, MD;
Ronald M. Fairman, MD; Richard Green, MD; Robert
Allen, MD; Rodney A. White, MD; Patricia Cole, MD;
Roy K. Greenberg, MD; Richard Heuser, MD; and
Thomas J. Fogarty, MD.
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